Skip to main content

Advertisement

SpringerLink
Log in

Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease

  • Inflammatory Bowel Disease (G Lichtenstein, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Infliximab and adalimumab biosimilars have been approved by the FDA and European Medicines Agency and have already been introduced to the international market. Availability into the US market is imminent. Biosimilars are highly similar to the reference biologic product but should not be referred to as, nor equated with, generic medications as no two biosimilars can ever be identical. Regulatory pathways for biosimilar approval consider the totality of evidence for biosimilar approvals, but the preponderance of development relies on analytic and functional testing and allows extrapolation between indications to reduce the financial burden of completing comparative clinical trials for each indication. Neither CT-P13 (infliximab biosimilar) nor ABP 501 (adalimumab biosimilar) was clinically tested in patients with inflammatory bowel disease prior to being submitted for approval by regulatory agencies. The body of available evidence suggests that these drugs will perform similarly to their originators. The pathway for interchangeability of biosimilars has yet to be clarified by federal regulators and currently remains determined by states within the USA. However, preliminary data suggests that switching from originator to biosimilar is safe with minimal differences in clinical efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation (CDER) and Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. April 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Last accessed 4/2/2016.

  2. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12. doi:10.1136/annrheumdis-2012-203091.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20. doi:10.1136/annrheumdis-2012-203090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. •• FDA Briefing Document, Arthritis Advisory Committee Meeting. CT-P13, a proposed biosimilar to Remicade (infliximab), Celltrion (BLA 125544). 2/9/2016. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf. Last accessed 3/25/2016. This outlines the in vitro and clinical comparisons of CT-P13 with European and American infliximab.

  5. European Medicines Agency: Remsima. European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed April 17, 2015.

  6. European Medicines Agency: Inflectra. European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002778/WC500151491.pdf. Accessed April 17, 2015.

  7. Papp K, Strober B, Bachelez H, Costanzo A, Weglowska J, Zhang N, et al. Results from a multicenter, phase 3 study evaluating the efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe plaque psoriasis. European Academy of Dermatology and Venerology (2015) Abstract P1736.

  8. Strober B, Armstrong A, Gordon K, Gottlieb A, Greenberg JD, Koo J, et al. Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. Washington DC: American Academy of Dermatology; 2016.

    Google Scholar 

  9. Cohen SB, Genovese MC, Choy EH, Perez-Ruiz F, Pablos JL, Zhang N, et al. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis. Arthritis Rheumatol. 2015;67(Suppl 10):2054.

    Google Scholar 

  10. Matsumoto AK, Pavelka K, Rizzo W, Gupta R, Shergy W, Haycaj P, et al. Secondary efficacy endpoints: results from a phase 3 study comparing ABP 501 with adalimumab in subjects with moderate to severe rheumatoid arthritis. Arthritis Rheumatol. 2015;67(Suppl 10):2757.

    Google Scholar 

  11. Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). 3/5/2010. http://hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/seb-pbu_2010-eng.php. Last accessed 4/14/2016.

  12. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. 5/30/2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Last accessed 4/14/2016.

  13. Epstein MS, Ehrenpreis ED, Kulkarni PM. Gastroenterology FD-RMCotACo. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014;109(12):1856–9. doi:10.1038/ajg.2014.151.

    Article  PubMed  Google Scholar 

  14. Bandyopadhyay S, Mahajan M, Mehta T, Singh A, Parikh A, Gupta A, et al. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2015;5:1–18.

    CAS  Google Scholar 

  15. de Ridder L, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA, et al. Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN Paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr. 2015;61(4):503–8. doi:10.1097/MPG.0000000000000903.

    Article  PubMed  Google Scholar 

  16. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.

    PubMed  PubMed Central  Google Scholar 

  17. Ben-Horin S, Casteele NV, Schreiber S, Lakatos P. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016; doi:10.1016/j.cgh.2016.05.023.

    Google Scholar 

  18. Summary basis of decision for Remsima (SBD). Health Canada. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_remsima_160195-eng.php. Accessed April 12 2016.

  19. •• FDA Briefing Document, Arthritis Advisory Committee Meeting. ABP 501—biosimilar candidate to adalimumab. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM511900.pdf. Last accessed 7/30/2016. This document provides comprehensive information on the clinical and laboratory experiments done evaluating ABP 501.

  20. Slevin SM, Egan LJ. New insights into the mechanisms of action of anti-tumor necrosis factor-alpha monoclonal antibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(12):2909–20. doi:10.1097/MIB.0000000000000533.

    Article  PubMed  Google Scholar 

  21. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. doi:10.1016/j.pharmthera.2007.10.001.

    Article  CAS  PubMed  Google Scholar 

  22. • Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013;14(12):1421–32. This is a comprehensive article outlining different mechanisms of action of anti-TNFs

    Article  CAS  PubMed  Google Scholar 

  23. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308–16. doi:10.1016/j.clim.2009.01.002.

    Article  CAS  PubMed  Google Scholar 

  24. • Velayudhan J, Chen YF, Rohrbach A, Pastula C, Maher G, Thomas H, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016; doi:10.1007/s40259-016-0185-2. This article provides details regarding the laboratory performance data available for ABP 501

    PubMed  PubMed Central  Google Scholar 

  25. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32. doi:10.1002/ibd.20225.

    Article  PubMed  Google Scholar 

  26. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21(3):251–8. doi:10.1111/j.1365-2036.2005.02309.x.

    Article  CAS  PubMed  Google Scholar 

  27. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine. 2004;28(2):67–74. doi:10.1016/j.cyto.2004.06.008.

    Article  CAS  PubMed  Google Scholar 

  28. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease. Gut. 2007;56(4):509–17. doi:10.1136/gut.2006.105379.

    Article  CAS  PubMed  Google Scholar 

  29. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology. 2001;121(5):1145–57.

    Article  CAS  PubMed  Google Scholar 

  30. Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity. Immunogenetics. 2013;65(4):265–71. doi:10.1007/s00251-013-0679-8.

    Article  CAS  PubMed  Google Scholar 

  31. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007;110(7):2561–4. doi:10.1182/blood-2007-01-070656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2004;19(5):511–9.

    Article  CAS  PubMed  Google Scholar 

  33. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn’s disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006;16(12):911–4. doi:10.1097/01.fpc.0000230421.12844.fd.

    Article  CAS  PubMed  Google Scholar 

  34. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248–57. doi:10.1002/art.23447.

    Article  CAS  PubMed  Google Scholar 

  35. Triggs JR, Hanauer SB. Role of antibody-dependent cellular cytotoxicity (ADCC) in treatment of IBD with anti-TNF agents. Unpublished work.

  36. Born T, Velayudhan J, Chen Y-F, Thomas H, Pastula C, Maher G et al. Demonstration of functional similarity comparing adalimumab to biosimilar candidate ABP 501. American college of rheumatology annual meeting 2014 Abstract 1503.

  37. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99(3):652–65. doi:10.1002/bit.21598.

    Article  CAS  PubMed  Google Scholar 

  38. Regulatory decision summary INFLECTRA. Health Canada. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds-sdr-infectra-184564-eng.php. Accessed October 9 2016.

  39. Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011;140(1):221–30. doi:10.1053/j.gastro.2010.10.008.

    Article  CAS  PubMed  Google Scholar 

  40. Reinisch W, Louis E, Danese S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):17–26. doi:10.1586/17474124.2015.1091306.

    Article  PubMed  Google Scholar 

  41. Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):321–38. doi:10.1007/s40259-016-0184-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–77. doi:10.4161/mabs.32221.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. doi:10.1186/s13075-016-0930-4.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2015;18:82. doi:10.1186/s13075-016-0981-6.

    Article  Google Scholar 

  45. Park W, Lee SJ, Yun J, Yoo DH. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, phase I study. Expert Rev Clin Immunol. 2015;11(Suppl 1):S25–31. doi:10.1586/1744666x.2015.1090311.

    Article  PubMed  Google Scholar 

  46. Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2016; doi:10.1136/annrheumdis-2015-208914.

    PubMed  Google Scholar 

  47. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211–28. doi:10.1007/s00228-009-0718-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008;48(6):681–95. doi:10.1177/0091270008316886.

    Article  CAS  PubMed  Google Scholar 

  49. Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, et al. Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn’s disease. Clin Pharmacokinet. 2015;54(5):551–62. doi:10.1007/s40262-014-0225-3.

    Article  CAS  PubMed  Google Scholar 

  50. Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104(6):1866–84. doi:10.1002/jps.24444.

    Article  CAS  PubMed  Google Scholar 

  51. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, et al. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016;54(4):315–22. doi:10.5414/CP202530.

    Article  CAS  PubMed  Google Scholar 

  52. Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969–75. doi:10.1097/mib.0000000000000709.

    Article  PubMed  Google Scholar 

  53. Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016; doi:10.1093/ecco-jcc/jjw087.

    PubMed  Google Scholar 

  54. Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2015; doi:10.1136/gutjnl-2015-309290. This article proves the cross-immunogenicity between infliximab and the infliximab biosimilar Remsima in IBD

    PubMed  Google Scholar 

  55. Ruiz-Arguello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martinez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016; doi:10.1136/annrheumdis-2015-208684.

    PubMed  Google Scholar 

  56. • Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133–40. doi:10.1093/ecco-jcc/jjv220. This is the largest cohort of patients to date who have been treated with CT-P13 in IBD

    Article  PubMed  Google Scholar 

  57. Kaur P, Krishnan E, Zhang N, Kaliyaperumal A. Biosimilar candidate ABP 501: immunogenicity results from 2 phase 3 studies. European Crohn’s and Colitis Organization Congress 2016 Abstract P515.

  58. Keil R, Wasserbauer M, Zadorova Z, Hajer J, Drastich P, Wohl P, et al. Scand J Gastroenterol. 2016:1–7. doi:10.3109/00365521.2016.1149883.

  59. Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44. doi:10.1586/17474124.2015.1091309.

    Article  PubMed  Google Scholar 

  60. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–12. doi:10.1111/jgh.12997.

    Article  CAS  PubMed  Google Scholar 

  61. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45–52. doi:10.1586/17474124.2015.1091308.

    Article  PubMed  Google Scholar 

  62. Farkas K, Rutka M, Balint A, Nagy F, Bor R, Milassin A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–62. doi:10.1517/14712598.2015.1064893.

    Article  PubMed  Google Scholar 

  63. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951–6. doi:10.1007/s10620-014-3392-z.

    Article  CAS  PubMed  Google Scholar 

  64. Murphy C, Sugrue K, Mohamad G, McCarthy J, Buckley M. Biosimilar but not the same. European Crohn’s and Colitis Organisation Congress 2015 Abstract P505.

  65. ClinicalTrials.gov. Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active Crohn’s disease (ClinicalTrials.gov identifier: NCT02096861). Available at: https://clinicaltrials.gov/ct2/show/NCT02096861. Last accessed July 28, 2016.

  66. Malickova K, Duricova D, Bortlik M, Hind’os M, Machkova N, Hruba V, et al. Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 2016;44(1):33–6. doi:10.1016/j.biologicals.2015.09.005.

    Article  CAS  PubMed  Google Scholar 

  67. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2015; doi:10.1111/1756-185X.12711.

    PubMed  PubMed Central  Google Scholar 

  68. Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015; doi:10.1136/annrheumdis-2015-207764.

    PubMed Central  Google Scholar 

  69. Cohen SB, Genovese MC, Choy EH, Perez-Ruiz F, Pablos JL, Zhang N, Kaur P. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).

  70. Fiorino G, Manetti N, Variola A, Bossa F, Rizzuto G, Guidi L, et al. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. European Crohn’s and Colitis Organisation Congress 2016 Abstract P544.

  71. Jarzebicka D, Banaszkiewicz A, Plocek A, Sieczkowska J, Gawronska A, Toporowska-Kowalska E, Kierkus J. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. European Crohn’s and Colitis Organization 2015. Abstract P295.

  72. ClinicalTrials.gov. The NOR-SWITCH study (ClinicalTrials.gov identifier: NCT02148640). Available at: https://clinicaltrials.gov/ct2/show/NCT02148640. Last acessed August 4, 2016.

  73. Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? PharmacoEconomics. 2016;34(6):609–16. doi:10.1007/s40273-015-0380-x.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University Langone Medical Center, NY, USA

    Shannon Chang MD

  2. Northwestern University Feinberg School of Medicine, 676 N. St Clair, Suite 1400, Chicago, IL, 60611, USA

    Stephen Hanauer MD

Authors
  1. Shannon Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Hanauer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Hanauer MD.

Ethics declarations

Conflict of Interest

Shannon Chang declares that she has no conflict of interest. Stephen Hanauer received grant support from Abbvie, Amgen, Boerhinger-Ingelheim, Celltrion, Hospira, Janssen, Merck, Samsung Bioepis, UCB.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, S., Hanauer, S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastro 15, 53–70 (2017). https://doi.org/10.1007/s11938-017-0122-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-017-0122-6

Keywords

Search

Navigation